The blockade of the TGF-β pathway is an efficient tool in the treatment of cancer, which attenuates Treg-mediated anti-tumor activity, enhances T cell cytotoxicity, and prompts T cell movement into the center of the tumor, leading to inducing robust anti-tumor immunity and tumor suppression (Figure 3) [98]. This evidence concerns the gene TGFB1 and neoplasm.